Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

1. Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling Interventions

Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling Interventions Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults who are overweight or obese and have additional CVD risk factors The USPSTF recommends offering or referring adults who (...) are overweight or obese and have additional cardiovascular disease (CVD) risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention. B View the Clinical Summary in Population Adults in primary care who are overweight or obese and have known cardiovascular risk factors Recommendation Offer or refer to intensive behavioral counseling interventions to promote a healthful diet and physical activity. Grade: B Risk Assessment Well-established

2020 U.S. Preventive Services Task Force

2. Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM Full Text available with Trip Pro

. (EARL) has established a standard ( , ) for intercenter harmonization for [ 18 F]FDG imaging. A standard for PET/CT imaging in inflammatory, infective, infiltrative, and innervation dysfunctional (4Is) cardiovascular diseases is currently lacking. Therefore, standards for PET imaging not limited to FDG are needed specifically designed for cardiovascular disorders. Goals The purpose of this document is to assist in performing PET/CT and PET/MR for cardiovascular imaging in the field of 4Is, starting (...) Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM | SpringerLink Search Search SpringerLink Search Procedural

2020 European Association of Nuclear Medicine

3. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University

2020 EvidenceUpdates

4. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search December 2020 November 2020 October 2020 September 2020 August 2020 July (...) 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association , PhD, MPH, FAHA, Chair , EdD, MS, FAHA , PhD, FAHA , MD, FAHA , MD, MS, MBA , MD, MPH, FAHA , MD, FAHA

2020 American Heart Association

5. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Full Text available with Trip Pro

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Oslo

2020 EvidenceUpdates

6. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Full Text available with Trip Pro

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Departamento de Medicina Preventiva, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, n° 740, Vila Clementino, São Paulo, SP CEP 04023-062 Brazil. 2 Sociedade Brasileira de Diabetes-SBD, Rua Afonso Braz, 579, Salas 72/74, Vila Nova Conceição, São Paulo, SP CEP 04511-011 Brazil. 3 Programa de Pós-Graduação Em Endocrinologia

2020 EvidenceUpdates

7. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. Full Text available with Trip Pro

plots and tabular presentations was performed. Associations for composite cardiovascular disease were: twofold for pre-eclampsia, stillbirth, and preterm birth; 1.5-1.9-fold for gestational hypertension, placental abruption, gestational diabetes, and premature ovarian insufficiency; and less than 1.5-fold for early menarche, polycystic ovary syndrome, ever parity, and early menopause. A longer length of breastfeeding was associated with a reduced risk of cardiovascular disease. The associations (...) contraceptives or progesterone only pill), pre-eclampsia, and recurrent pre-eclampsia; 1.5-1.9-fold for current use of combined oral contraceptives, gestational diabetes, and preterm birth; and less than 1.5-fold for polycystic ovary syndrome. The association for heart failure was fourfold for pre-eclampsia. No association was found between cardiovascular disease outcomes and current use of progesterone only contraceptives, use of non-oral hormonal contraceptive agents, or fertility treatment.From menarche

2020 BMJ

8. Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS

Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report available at https://muhc.ca/tau Technology Assessment Unit of the McGill University Health Centre (MUHC) Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report number: 84 DATE: May 14 th , 2020 Report available at https://muhc.ca/tau Report prepared (...) cardiovascular disease at the MUHC RUISSS. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2020 May 14. Report no. 84. 64 pagesApoB iii 14 May 2020 Technology Assessment Unit, MUHC ACKNOWLEDGEMENTS The expert assistance of the following individuals is gratefully acknowledged: ? David Blank, MUHC Site Chief, Division of Biochemistry, Department of Clinical Laboratory Medicine, MUHC ? Allan Sniderman, Cardiologist at the MUHC and Senior Scientist

2020 McGill TAU reports

9. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. (Abstract)

Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations.On 6 August to 9

2020 Annals of Internal Medicine

10. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. (Abstract)

Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. Strategies to improve patients' tolerance of and adherence to statins may enhance the effectiveness of dyslipidemia treatment in those at risk for cardiovascular disease (CVD).To assess the benefits and harms of interventions to improve statin

2020 Annals of Internal Medicine

11. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (Abstract)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. This is the second update of the review first published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.To determine if lower blood pressure targets (135/85 mmHg or less) are associated with reduction in mortality and morbidity as compared with standard blood pressure targets (140 to 160/90 to 100 mmHg or less) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive

2020 Cochrane

12. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Full Text available with Trip Pro

in both groups across all categories of eGFR. Conclusions: In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2. Keywords: Acute coronary syndrome; Chronic kidney disease; Glomerular filtration rate; Low-density lipoprotein cholesterol; Major adverse cardiovascular events; PCSK9 inhibition. © The Author(s) 2020. Published by Oxford (...) Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial - PubMed This site needs JavaScript to work properly. Please enable

2020 EvidenceUpdates

13. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk

Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Aug 18;76(7):781-793. doi: 10.1016/j.jacc.2020.06.040. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk , , , , , , , , , Affiliations Expand Affiliations 1 Emory

2020 EvidenceUpdates

14. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease Full Text available with Trip Pro

testing, field testing and/or after muscular strength testing 13 Figure 3a and 3b SCORE charts for European populations of countries at HIGH and LOW cardiovascular disease risk 15 Figure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals with risk factors for and possible subclinical chronic coronary syndrome before engaging in sports for individuals aged >35 years 18 Figure 5 Clinical evaluation and recommendations for sports participation in individuals with established (...) Bicuspid aortic valve BMI Body mass index BP Blood pressure BrS Brugada syndrome CAC Coronary artery calcium CAD Coronary artery disease CCS Chronic coronary syndrome CCTA Coronary computed tomography angiography CHD Congenital heart disease CKD Chronic kidney disease CMD Coronary microvascular dysfunction CMR Cardiac magnetic resonance CPET Cardiopulmonary exercise test CPR Cardiopulmonary resuscitation CT Computed tomography CV Cardiovascular CVA Cerebrovascular accident CVD Cardiovascular disease

2020 European Society of Cardiology

15. Reduction in saturated fat intake for cardiovascular disease. (Abstract)

to alter dietary fats and achieving a reduction in saturated fat; 3) compared with higher saturated fat intake or usual diet; 4) not multifactorial; 5) in adult humans with or without cardiovascular disease (but not acutely ill, pregnant or breastfeeding); 6) intervention duration at least 24 months; 7) mortality or cardiovascular morbidity data available.Two review authors independently assessed inclusion, extracted study data and assessed risk of bias. We performed random-effects meta-analyses, meta (...) Reduction in saturated fat intake for cardiovascular disease. Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally, it is unclear whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein.To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA

2020 Cochrane

16. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

published 23 Jul 2020 Circulation: Genomic and Precision Medicine. ;0 Abstract Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families (...) Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article

2020 American Heart Association

17. Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged (...) in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association , MD, PhD, Chair , MD, FAHA, Co-chair , PhD, FAHA , MD, FAHA , MD, PhD , MD, PhD, FAHA , PhD, FAHA , MD, PhD, FAHA , PhD, FAHA , MD

2020 American Heart Association

18. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial Full Text available with Trip Pro

Abstract Importance: Persons with serious mental illness have a cardiovascular disease mortality rate more than twice that of the overall population. Meaningful cardiovascular risk reduction requires targeted efforts in this population, who often have psychiatric symptoms and cognitive impairment. Objective: To determine the effectiveness of an 18-month multifaceted intervention incorporating behavioral counseling, care coordination, and care management for overall cardiovascular risk reduction (...) in adults with serious mental illness. Design, setting, and participants: This randomized clinical trial was conducted from December 2013 to November 2018 at 4 community mental health outpatient programs in Maryland. The study recruited adults with at least 1 cardiovascular disease risk factor (hypertension, diabetes, dyslipidemia, current tobacco smoking, and/or overweight or obesity) attending the mental health programs. Of 398 participants screened, 269 were randomized to intervention (132

2020 EvidenceUpdates

19. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Full Text available with Trip Pro

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators COMPASS Steering

2020 EvidenceUpdates

20. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Full Text available with Trip Pro

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug (...) to 1.74).Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. (Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.).Copyright © 2020

2020 NEJM